What is the expected growth forecast for the PNH Treatment market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the PNH Treatment market?

Key drivers include increasing disease awareness and advancements in treatment options.

What are the major challenges facing the PNH Treatment market?

Challenges include high treatment costs and limited access to healthcare in developing regions.

Which regions are leading the PNH Treatment market?

North America and Europe are currently the leading regions in the market.

Who are the top companies in the PNH Treatment market?

Top companies include Alexion Pharmaceuticals and Pfizer, among others.

What future opportunities exist in the PNH Treatment market?

Future opportunities include the development of new therapies and expansion into emerging markets.

How is technology impacting the PNH Treatment market?

Technology is improving diagnosis and treatment options, enhancing patient outcomes.

What is the current regulatory landscape for the PNH Treatment market?

The regulatory landscape is evolving, with ongoing updates to treatment guidelines and approvals.

What is the future outlook for the PNH Treatment market?

The future outlook is positive, with expected growth driven by increasing demand for effective treatments.

What Is the Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Worth in 2026?

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Application (Hospital, Clinic, Other), by Types (Monoclonal Antibodies Therapy, Immunosuppressive Drugs, Hematopoietic Stem Cell Transplantation), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 130

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 130

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size | CAGR 9.2 Forecast 2033

What Is the Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Worth in 2026?

🏭 Healthcare🌍 Global

Pages: 130

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 130

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview

The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market refers to the global industry focused on developing and marketing therapies for PNH, a rare and debilitating blood disorder. As the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market size is expected to reach approximately $4.8 billion by 2026, the growth outlook and market forecast indicate a significant expansion of the industry, driven by advancements in treatment options and increasing awareness about the disease. The scope of this market encompasses various treatments, including pharmacological interventions, and therapies, such as complement inhibitors, which are transforming the landscape of PNH management.

Loading chart…

Key forces shaping the PNH Treatment industry include technology shifts towards more targeted and effective therapies, regulations supporting the development of orphan drugs, and competitive intensity among market players. The largest region for PNH treatment is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing healthcare expenditure and growing awareness about rare diseases. With a CAGR of around 10%, the PNH treatment market is poised for significant industry expansion, offering opportunities for pharmaceutical companies, researchers, and healthcare providers to collaborate and improve patient outcomes.

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 billion
Revenue forecast in 2033	4.65 billion
Growth rate	CAGR of 9.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Amoun Pharmaceuticals; EIPICO; Minapharm Pharmaceuticals; Pharco Pharmaceuticals; Alexion Pharmaceuticals; Alnylam Pharmaceuticals; Akari Therapeutics; Amgen; CSL Behring; Bioverativ; F. Hoffmann-La Roche Ltd; Novartis AG; Amgen Inc; Teva Pharmaceutical; Abbott
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market is experiencing significant growth, driven by increasing awareness and advancements in treatment options. The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market size is expected to expand substantially, with a promising growth forecast.

Growth Drivers2 items

Increasing prevalence of PNH and improving diagnosis rates are driving the demand for effective treatments, contributing to the expansion of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market.

Advances in research and development, such as the introduction of novel therapeutics and innovative drug delivery systems, are expected to fuel the growth forecast of the PNH treatment market.

Restraints2 items

High treatment costs and limited access to novel therapies in developing countries are hindering the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market size, restricting its potential growth.

Stringent regulatory requirements and intense competition among market players are challenging the profitability of companies operating in the PNH treatment market, affecting the overall growth forecast.

Opportunities2 items

Emerging markets, particularly in Asia-Pacific and Latin America, offer significant opportunities for the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market to expand, driven by increasing healthcare expenditure and improving infrastructure.

Collaborations and partnerships between pharmaceutical companies, research institutions, and healthcare providers can facilitate the development of innovative treatments, enhancing the growth forecast of the PNH treatment market.

Challenges2 items

Managing the complexity of PNH treatment, including the need for ongoing monitoring and potential side effects, poses significant challenges for healthcare providers and patients, impacting the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market size.

Ensuring equitable access to novel therapies, particularly in resource-constrained settings, remains a major challenge, affecting the overall growth forecast of the PNH treatment market and limiting its potential impact.

Market Segmentation

Loading chart…

The Application segment of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market refers to the various uses of treatments for PNH, including intravenous and subcutaneous administration. This segment contributes to the overall market size by accounting for the different ways in which treatments are administered to patients. The application segment is a crucial aspect of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment segmentation as it helps in understanding the patient's preference and the ease of administration.

The Types segment of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market includes subtypes such as monoclonal antibodies and complement inhibitors. This segment plays a significant role in determining the overall market size as it accounts for the different types of treatments available for PNH. Understanding the types of treatments available helps in identifying the most effective treatment options for patients, which in turn contributes to the growth of the market. The types segment is an essential part of the market taxonomy as it enables the identification of the most promising treatment options.

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Segmentation Breakdown8 items

Application

Hospital

Clinic

Other

Types

Monoclonal Antibodies Therapy

Immunosuppressive Drugs

Hematopoietic Stem Cell Transplantation

Regional Insights

Loading chart…

The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of novel therapies, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for each region include: North America, driven by demographics and ecosystem maturity; Europe, fueled by policies and infrastructure; Asia Pacific, driven by adoption and investments; Latin America, influenced by demographics and infrastructure; and Middle East & Africa, shaped by policies and ecosystem maturity. The regional forecast suggests that these factors will significantly impact the PNH Treatment market growth in the coming years.

Regional Insights5 items

North America: driven by demographics and ecosystem maturity, with a focus on innovative treatments

Europe: fueled by policies and infrastructure, with an emphasis on patient access to novel therapies

Asia Pacific: driven by adoption and investments, with a growing demand for PNH treatments

Latin America: influenced by demographics and infrastructure, with opportunities for market expansion

Middle East & Africa: shaped by policies and ecosystem maturity, with a need for increased awareness and access to PNH treatments

Competitive Landscape

The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment competitive landscape is moderately consolidated, with a mix of global players and local companies. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The market is driven by both global players, such as Alexion Pharmaceuticals, and local/regional companies, like Amoun Pharmaceuticals. Understanding the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment competitive landscape is crucial for companies to navigate the market effectively.

Companies in the PNH treatment market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. The following companies have notable strategic focuses:

Alexion Pharmaceuticals: innovation pipeline

Amoun Pharmaceuticals: local manufacturing

EIPICO: regional expansion

Minapharm Pharmaceuticals: OEM tie-ups

Pharco Pharmaceuticals: vertical integration

Alnylam Pharmaceuticals: premium pricing

Key Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Companies15 items

Amoun Pharmaceuticals

EIPICO

Minapharm Pharmaceuticals

Pharco Pharmaceuticals

Alexion Pharmaceuticals

Alnylam Pharmaceuticals

Akari Therapeutics

Amgen

CSL Behring

Bioverativ

F. Hoffmann-La Roche Ltd

Novartis AG

Amgen Inc

Teva Pharmaceutical

Abbott

Market Ecosystem

The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of treatments, as well as the provision of related services. The ecosystem is characterized by a complex interplay of participants, each playing a distinct role in the delivery of PNH treatments.

Raw material suppliers — providing active pharmaceutical ingredients

OEMs/manufacturers — producing PNH treatments

Technology providers — developing innovative treatment platforms

Distributors/channel partners — delivering treatments to healthcare providers

Service providers/after-sales — offering patient support and monitoring services

End users/buyers — patients and healthcare providers purchasing PNH treatments

Regulators/standards bodies — overseeing treatment approvals and safety standards

In the PNH Treatment ecosystem, control points are largely influenced by regulators and standards bodies, who oversee treatment approvals and safety standards. Dependency risks arise from input constraints, such as the availability of active pharmaceutical ingredients, as well as standards and approvals. Switching costs and partnerships can also impact the ecosystem, particularly in terms of interoperability requirements between different treatment platforms. Furthermore, the ecosystem may differ by region due to varying regulatory frameworks and healthcare systems, highlighting the need for a nuanced understanding of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment ecosystem through a thorough value chain analysis.

Recent Industry Insights

The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between key players have focused on advancing research and development of innovative therapies. Notably, several mergers and acquisitions have taken place, aimed at expanding product portfolios and strengthening market presence. Furthermore, the launch of novel products and technologies has improved treatment outcomes, enhancing the overall quality of life for patients. Regulatory changes have also played a crucial role in shaping the industry, with a greater emphasis on approving more targeted and effective treatments. A shift in consumer trends has been observed, with a growing demand for personalized medicine and increased awareness about PNH.

In addition, the industry has seen significant funding rounds and expansions, driving growth and innovation. These developments are expected to continue, with the PNH treatment market poised for further expansion. As research advances and new therapies emerge, the industry is likely to experience sustained growth, driven by increasing awareness and improving treatment options. The future of the PNH treatment industry looks promising, with a focus on developing more effective and targeted therapies.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market outlook. The market attractiveness is moderate, driven by the growing prevalence of PNH and the increasing demand for effective treatments. The competitive intensity is high, with several key players competing for market share.

The long-term outlook for the PNH treatment market is positive, with innovative therapies and rising awareness expected to drive growth. The innovation landscape is evolving, with a focus on developing more targeted and effective treatments. However, the demand-supply balance is a key risk factor, as the limited availability of certain treatments may impact patient access.

Overall, the PNH treatment market is expected to experience steady growth, driven by the increasing demand for effective treatments and the development of innovative therapies. Decision-makers should be aware of the key risk factors, including the demand-supply balance and the competitive intensity, to make informed decisions and capitalize on the growth opportunities in the PNH treatment market.

12 items

1. Executive Summary

2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Competition by Key Manufacturers

9.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Amoun Pharmaceuticals

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. EIPICO

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Minapharm Pharmaceuticals

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Pharco Pharmaceuticals

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Alexion Pharmaceuticals

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Alnylam Pharmaceuticals

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Akari Therapeutics

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Amgen

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. CSL Behring

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Bioverativ

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. F. Hoffmann-La Roche Ltd

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Novartis AG

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Amgen Inc

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Teva Pharmaceutical

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Abbott

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

Figure 4: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Drivers

Figure 5: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Challenges

Figure 6: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Trends

Figure 7: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Opportunity

Figure 8: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Restraint

Figure 9: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Value (USD Million) By Region

Figure 19: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Value (USD Million) By Region

Figure 27: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share (%) By: Regions (2032)

Figure 28: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Volume (K) By Region

Figure 29: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Value (USD Million) By Region

Figure 37: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share (%) By: Regions (2032)

Figure 38: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Volume (K) By Region

Figure 39: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

125 items

Table 1: Market Segmentation Analysis

Table 2: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Value (USD Million) By Region

Table 14: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Volume (K) By Region

Table 31: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Amoun Pharmaceuticals Basic Information And Sales Area

Table 52: Amoun Pharmaceuticals. Products Portfolio

Table 53: EIPICO Basic Information And Sales Area

Table 54: EIPICO. Products Portfolio

Table 55: Minapharm Pharmaceuticals Basic Information And Sales Area

Table 56: Minapharm Pharmaceuticals. Products Portfolio

Table 57: Pharco Pharmaceuticals Basic Information And Sales Area

Table 58: Pharco Pharmaceuticals. Products Portfolio

Table 59: Alexion Pharmaceuticals Basic Information And Sales Area

Table 60: Alexion Pharmaceuticals. Products Portfolio

Table 61: Alnylam Pharmaceuticals Basic Information And Sales Area

Table 62: Alnylam Pharmaceuticals. Products Portfolio

Table 63: Akari Therapeutics Basic Information And Sales Area

Table 64: Akari Therapeutics. Products Portfolio

Table 65: Amgen Basic Information And Sales Area

Table 66: Amgen. Products Portfolio

Table 67: CSL Behring Basic Information And Sales Area

Table 68: CSL Behring. Products Portfolio

Table 69: Bioverativ Basic Information And Sales Area

Table 70: Bioverativ. Products Portfolio

Table 71: F. Hoffmann-La Roche Ltd Basic Information And Sales Area

Table 72: F. Hoffmann-La Roche Ltd. Products Portfolio

Table 73: Novartis AG Basic Information And Sales Area

Table 74: Novartis AG. Products Portfolio

Table 75: Amgen Inc Basic Information And Sales Area

Table 76: Amgen Inc. Products Portfolio

Table 77: Teva Pharmaceutical Basic Information And Sales Area

Table 78: Teva Pharmaceutical. Products Portfolio

Table 79: Abbott Basic Information And Sales Area

Table 80: Abbott. Products Portfolio

Table 81: Global Market Value (USD Million) (2025-2032) By Application

Table 82: Global Market Share (%) By Application (2032)

Table 83: Global Market Value (USD Million) (2025-2032) By Types

Table 84: Global Market Share (%) By Types (2032)

Table 85: Global Market Volume (K) (2025-2032) By Application

Table 86: Global Market Share (%) By Application (2032)

Table 87: Global Market Volume (K) (2025-2032) By Types

Table 88: Global Market Share (%) By Types (2032)

Table 89: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Value (USD Million) By Region

Table 90: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share (%) By Region (2025-2032)

Table 91: North America Market Value (USD Million) (2025-2032) By Country

Table 92: North America Market Value (USD Million) (2025-2032) By Application

Table 93: North America Market Value (USD Million) (2025-2032) By Types

Table 94: Europe Market Value (USD Million) (2025-2032) By Country

Table 95: Europe Market Value (USD Million) (2025-2032) By Application

Table 96: Europe Market Value (USD Million) (2025-2032) By Types

Table 97: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 98: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 99: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 100: South America Market Value (USD Million) (2025-2032) By Country

Table 101: South America Market Value (USD Million) (2025-2032) By Application

Table 102: South America Market Value (USD Million) (2025-2032) By Types

Table 103: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 104: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 105: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 106: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Volume (K) By Region

Table 107: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share (%) By Region (2025-2032)

Table 108: North America Market Volume (K) (2025-2032) By Country

Table 109: North America Market Volume (K) (2025-2032) By Application

Table 110: North America Market Volume (K) (2025-2032) By Types

Table 111: Europe Market Volume (K) (2025-2032) By Country

Table 112: Europe Market Volume (K) (2025-2032) By Application

Table 113: Europe Market Volume (K) (2025-2032) By Types

Table 114: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 115: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 116: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 117: South America Market Volume (K) (2025-2032) By Country

Table 118: South America Market Volume (K) (2025-2032) By Application

Table 119: South America Market Volume (K) (2025-2032) By Types

Table 120: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 121: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 122: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 123: Research Programs/Design For This Report

Table 124: Key Data Information From Secondary Sources

Table 125: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 billion
Revenue forecast in 2033	4.65 billion
Growth rate	CAGR of 9.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Amoun Pharmaceuticals; EIPICO; Minapharm Pharmaceuticals; Pharco Pharmaceuticals; Alexion Pharmaceuticals; Alnylam Pharmaceuticals; Akari Therapeutics; Amgen; CSL Behring; Bioverativ; F. Hoffmann-La Roche Ltd; Novartis AG; Amgen Inc; Teva Pharmaceutical; Abbott
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options